Biogen Inc.
Biotechnology and PharmaceuticalsFounded 1978- Updated June 2025
Reviewed by Swet Parvadiya
Last reviewed: June 2025
CorpDigest
Biogen Inc.
Financial Performance
Last reviewed: June 2025 · By Swet Parvadiya
Revenue
$9.62B
Market Cap
$32.0B
Net Income
$1.2B
Employees
8,500
Revenue declining from $10.17 billion in 2022 to $9.62 billion in 2024 tells you the story of MS biosimilar competition arriving at the precise moment that the Alzheimer's commercial strategy stumbled. Tecfidera, Biogen's oral MS drug, faced biosimilar competition that the company had delayed through patent litigation but could not prevent indefinitely. As Tecfidera revenue fell, Leqembi needed to generate growth that it has not yet produced at scale. Net income of $1.2 billion in FY2024 on $9.62 billion in revenue is a 12.5% net margin — lower than the peak profitability of the MS-franchise years but positive and sustainable. The Pharmaceuticals gross margin exceeded 75% in FY2024, reflecting the pricing power of complex biologics that biosimilar manufacturers have difficulty replicating precisely enough to gain formulary substitution. R&D expenditure of approximately $3.24 billion in FY2024 — 33.7% of revenue — is disproportionately high for a company this size and reflects both the capital requirements of late-stage clinical trials and the strategic necessity of finding a post-MS growth driver. Forty molecules in clinical development require significant ongoing investment even when most will not reach approval. Market capitalization of approximately $32 billion against $9.62 billion in revenue prices Biogen at roughly 3.3x revenue — a deep discount to the 8-12x multiples that growing pharmaceutical companies command. The market is pricing the company as a business with declining legacy revenue and uncertain replacement — reasonable given the evidence, but potentially mispriced if Leqembi adoption accelerates or if pipeline assets in stroke, Parkinson's, or ALS deliver Phase III results that the market currently assigns low probability to.
Revenue Trend Analysis
YoY Change
-1.1%
2-Year CAGR
-2.7%
Peak Year
2022
Trend
Declining Trend
Biogen Inc. has reported revenue across 3 fiscal years, compounding at -2.7% annually over 2 years. The most recent year saw a 1.1% decline versus the prior year. Revenue peaked in 2022 at $10.2B. Out of 2 reported periods, 0 showed growth and 2 showed a decline.
| Fiscal Year | Revenue | Net Income | YoY Change |
|---|---|---|---|
| FY2024 | $9.6B | $1.2B | -1.1% |
| FY2023 | $9.7B | — | -4.3% |
| FY2022 | $10.2B | — | — |
Source: SEC EDGAR filings, annual earnings releases, and verified financial disclosures.
Click any row to see year details.
Biogen's revenue peaked at $14.4 billion in 2019 before Tecfidera lost patent protection, declining to $9.62 billion by 2024 — a $4.8 billion revenue cliff representing one of pharma's most severe patent-driven declines outside of acquisitions. The decline reflects Tecfidera generic competition reducing its revenue from $4.4 billion to under $200 million, partially offset by Vumerity growth, Spinraza stability, and modest Leqembi launch. Operating margins compressed from 50%+ at peak to 25-30% as Biogen maintained R&D and SG&A spending against declining revenue, and the company has implemented multiple restructurings totalling $1+ billion in cost reductions to align spending with the smaller revenue base.
Biogen's earnings recovery strategy combines pipeline-driven new product launches (Leqembi, Zurzuvae, Skyclarys, Qalsody), cost discipline (Project Fit reducing operating expenses by $1 billion annually), and bolt-on M&A like the 2023 Reata Pharmaceuticals acquisition for $7.3 billion that added Skyclarys (Friedreich's ataxia, $200 million growing to $1B+ potential). CEO Viehbacher has explicitly committed to disciplined capital allocation — not chasing growth at the expense of returns — and the company targets returning to $10+ billion in revenue by 2027-2028 if pipeline drugs achieve commercial success. The strategy requires balancing aggressive R&D investment with operational efficiency, an inherent tension that creates execution risk for a smaller biotech competing against pharma giants.
Biogen generates approximately $2-2.5 billion in annual operating cash flow despite the revenue decline, allocating capital across R&D (€2.4B), strategic acquisitions ($7.3B Reata 2023), and share buybacks ($1.5B in 2024). The company suspended significant buybacks during the Reata integration and Aduhelm crisis, preserving cash for pipeline investment, but resumed return of capital as Leqembi launch progressed. Biogen maintains $1-2 billion in cash with limited debt ($6.5 billion long-term), preserving financial flexibility for additional acquisitions to fill the post-Tecfidera revenue gap. Free cash flow generation has compressed from $4 billion at peak to $1.5-2 billion now, reflecting margin pressure that requires either revenue recovery or further cost reduction to support continued investment.
Aduhelm's commercial failure cost Biogen $500+ million in inventory write-downs and impairments in 2022, but the deeper financial damage came from the strategic distraction — management bandwidth consumed by Congressional investigations, Medicare coverage disputes, and the eventual January 2024 discontinuation. The drug's projected $1+ billion peak revenue was excluded from forward estimates, and the controversy damaged Biogen's reputation with payers and physicians who became sceptical of subsequent Alzheimer's drug Leqembi's clinical claims. Aduhelm's failure also delayed Biogen's CEO transition — predecessor Michel Vounatsos stepping down in 2022 after the failure — and forced the Reata acquisition as a strategic alternative to internal pipeline that had become tainted.
Using these figures? Please credit CorpDigest with a link.
CorpDigest. "Biogen Inc. Revenue & Financials." CorpDigest, https://corpdigest.com/company/biogen/financials.<div style="font-family:system-ui,sans-serif;font-size:14px;line-height:1.5;border:1px solid #e2e8f0;border-radius:8px;padding:12px 16px;max-width:520px"><strong>Biogen Inc. reported $10B in revenue (FY2024).</strong><br>Source: <a href="https://corpdigest.com/company/biogen/financials" target="_blank" rel="noopener">CorpDigest — Biogen Inc. financials</a></div>